THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE

被引:12
作者
Shibuya, Kelly [1 ]
Ali, Khazvla F. [2 ]
Ji, Xinge [3 ]
Milinoivh, Alex [3 ]
Bauman, Janine [3 ]
Kattan, Michael W. [3 ]
Pantalone, Kevin M. [2 ]
Burguera, Bartolome [1 ,2 ,4 ]
机构
[1] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[2] Cleveland Clin, Endocrinol & Metab Inst, 9500 Eudid Ave,M62, Cleveland, OH 44195 USA
[3] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44195 USA
[4] Natl Diabet & Obes Res Inst, Tradition, MS USA
关键词
OBESITY; PHARMACOTHERAPY; ASSOCIATION; ADULTS;
D O I
10.4158/EP-2019-0081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The effectiveness of anti-obesity medications (AOMs) outside of clinical trials is unclear. The objective of this study was to compare the short-term effectiveness of AOMs in real-world practice. Methods: This retrospective study included adults aged >= 18 years, with body mass index >= 30kg/m(2) or >= 27 kg/m(2) with at least one obesity-related comorbidity who were prescribed phentermine hydrochloride, phenterminetopiramate, bupropion-naltrexone, or lorcaserin for 12 consecutive weeks between 2006 and 2016 at a large tertiary healthcare system. Propensity score-matched cohorts were created for each pair of AOMs. The primary outcomes were percent and absolute weight loss from baseline after 12 weeks. A prediction model was constructed to estimate weight loss with different AOMs based on demographic and clinical data. Results: Of the 3,411 patients included in this study, patients lost an average of 3.45% of body weight from baseline. All AOMs were associated with a significant weight loss from baseline (P<.0001). Patients lost the highest percentage of body weight on phentermine hydrochloride (3.75 +/- 5.66%), followed by phentermine-topiramate (3.63 +/- 5.7%), bupropion-naltrexonc (2.66 +/- 5.03%), and lorcaserin (1.84 +/- 6.69%). In propensity-matched cohorts, patients taking phentermine hydrochloride lost more weight than those taking lorcaserin or bupropion-naltrexone, and patients taking phentermine topiramate lost more weight than patients taking lorcaserin. Conclusion: in real-world practice, AOMs are associated with clinically meaningful weight loss of 2 to 4% after 12 weeks. In this study, phentermine hydrochloride and phentermine topiramate produced the most weight loss. AOMs should be seriously considered as part of the armamentarium to treat patients with obesity.
引用
收藏
页码:1022 / 1028
页数:7
相关论文
共 20 条
  • [1] Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
    Allison, David B.
    Gadde, Kishore M.
    Garvey, William Timothy
    Peterson, Craig A.
    Schwiers, Michael L.
    Najarian, Thomas
    Tam, Peter Y.
    Troupin, Barbara
    Day, Wesley W.
    [J]. OBESITY, 2012, 20 (02) : 330 - 342
  • [2] Pharmacotherapy for obesity: What you need to know
    Bersoux, Sophie
    Byun, Tina H.
    Chaliki, Swarna S.
    Poole, Kenneth G., Jr.
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2017, 84 (12) : 951 - 958
  • [3] Trends in Obesity Among Adults in the United States, 2005 to 2014
    Flegal, Katherine M.
    Kruszon-Moran, Deanna
    Carroll, Margaret D.
    Fryar, Cheryl D.
    Ogden, Cynthia L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (21): : 2284 - 2291
  • [4] The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
    Fujioka, K.
    Plodkowski, R.
    O'Neil, P. M.
    Gilder, K.
    Walsh, B.
    Greenway, F. L.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2016, 40 (09) : 1369 - 1375
  • [5] Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
    Fujioka, Ken
    O'Neil, Patrick M.
    Davies, Melanie
    Greenway, Frank
    Lau, David C. W.
    Claudius, Birgitte
    Skjoth, Trine Vang
    Jensen, Christine Bjorn
    Wilding, John P. H.
    [J]. OBESITY, 2016, 24 (11) : 2278 - 2288
  • [6] AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
    Garvey, W. Timothy
    Mechanick, Jeffrey I.
    Brett, Elise M.
    Garber, Alan J.
    Hurley, Daniel L.
    Jastreboff, Ania M.
    Nadolsky, Karl
    Pessah-Pollack, Rachel
    Plodkowski, Raymond
    [J]. ENDOCRINE PRACTICE, 2016, 22 : 1 - 203
  • [7] GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397
  • [8] Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Greenway, Frank L.
    Fujioka, Ken
    Plodkowski, Raymond A.
    Mudaliar, Sunder
    Guttadauria, Maria
    Erickson, Janelle
    Kim, Dennis D.
    Dunayevich, Eduardo
    [J]. LANCET, 2010, 376 (9741) : 595 - 605
  • [9] Use of Prescription Antiobesity Drugs in the United States
    Hampp, Christian
    Kang, Elizabeth M.
    Borders-Hemphill, Vicky
    [J]. PHARMACOTHERAPY, 2013, 33 (12): : 1299 - 1307
  • [10] Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee